{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059496","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.730912+00:00","generated_at":"2026-06-02T00:59:12.645111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND","bullets":["Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.","Cash and equivalents $247.6M as of March 31, 2024; expected runway into H2 2026.","On track to initiate Phase 1 of ADI-001 in lupus nephritis in Q2 2024; data expected Q4 2024 or Q1 2025.","Preclinical data for ADI-270 presented at ASGCT; IND for renal cell carcinoma planned Q2 2024.","Enrolling MCL patients in ADI-001 GLEAN study; clinical update with 6-month data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059496","json":"https://secwatch.observer/filing/0000950170-24-059496.json","markdown":"https://secwatch.observer/filing/0000950170-24-059496.md","text":"https://secwatch.observer/filing/0000950170-24-059496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/acet-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:59:12.645111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bd6e01bdda89a4e979be66b3687f3d69455729b","claim":"Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $28.0 million"},{"label":"EPS","value":"$0.35 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}